Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
RHHBY Roche $0.00 (0.00%) 13:54 04/18/19 04/18 13:54 04/18/19 13:54 Conference/Events	Roche management to meet with JPMorgan » Meeting to be held in… Meeting to be held in London on April 23 hosted by JPMorgan. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Apr 03 May 06 Aug 18 Aug 19 Aug 02 Sep 04 Nov

Wednesday
IONS Ionis Pharmaceuticals $71.20 -12.06 (-14.48%) , RHHBY Roche $0.00 (0.00%) 13:50 04/17/19 04/17 13:50 04/17/19 13:50 Recommendations	Ionis Pharmaceuticals, Roche analyst commentary at Wells Fargo » Ionis pullback on Roche… Ionis pullback on Roche update a buying opportunity, says Wells Fargo. Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators. IONS Ionis Pharmaceuticals $71.20 -12.06 (-14.48%) RHHBY Roche $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Apr 03 May 06 May 06 Aug 18 Aug 19 Aug 02 Sep 04 Nov
IONS Ionis Pharmaceuticals $71.52 -11.74 (-14.10%) , RHHBY Roche $0.00 (0.00%) 13:41 04/17/19 04/17 13:41 04/17/19 13:41 Recommendations	Ionis Pharmaceuticals, Roche analyst commentary at Wells Fargo » Wells says Ionis weakness… Wells says Ionis weakness on Roche Huntington's update a buying opportunity IONS Ionis Pharmaceuticals $71.52 -11.74 (-14.10%) RHHBY Roche $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Apr 03 May 06 May 06 Aug 18 Aug 19 Aug 02 Sep 04 Nov
RHHBY Roche $0.00 (0.00%) 05:45 04/17/19 04/17 05:45 04/17/19 05:45 Earnings	Roche raises FY19 revenue guidance to mid-single digit growth » Sales are now expected to… Sales are now expected to grow in the mid-single digit range, at constant exchange rates. Core EPS are targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Apr 06 Aug 18 Aug 19 Aug 02 Sep 04 Nov
RHHBY Roche $0.00 (0.00%) 05:45 04/17/19 04/17 05:45 04/17/19 05:45 Earnings	Roche reports Q1 revenue CHF 14.83B vs. CHF 13.58B last year » Commenting on the… Commenting on the Group's sales, Roche CEO Severin Schwan said: "We have started the year with strong sales growth, driven by the newly launched products in our Pharmaceuticals Division. Demand for our new medicines remains high. Health authorities granted a number of important approvals for our medicines in the first quarter. These include the first cancer immunotherapies for triple-negative breast cancer and small cell lung cancer, two diseases with high unmet patient need. Based on our performance in the first quarter, we raise the outlook for the full-year." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Apr 06 Aug 18 Aug 19 Aug 02 Sep 04 Nov

Over a week ago
ALC Alcon $57.23 -1.15 (-1.97%) , AAPL Apple $199.55 -0.04 (-0.02%) … 11:20 04/10/19 04/10 11:20 04/10/19 11:20 On The Fly	Apple downgrade, Tesla initiation among today's top analyst calls » Check out today's top… Open Full Text ALC Alcon $57.23 -1.15 (-1.97%) AAPL Apple $199.55 -0.04 (-0.02%) TSLA Tesla $275.35 3.22 (1.18%) GILD Gilead $67.33 1.24 (1.88%) JWN Nordstrom $44.59 0.44 (1.00%) UA Under Armour $19.13 0.42 (2.24%) UAA Under Armour $21.21 0.5 (2.41%) NVS Novartis $82.08 -1.32 (-1.58%) RHHBY Roche $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Apr 16 Apr 17 Apr 22 Apr 24 Apr 30 Apr 02 May 08 May 09 May 09 May 18 May 03 Jun 18 Aug 19 Aug 02 Sep 04 Nov
NVS Novartis $83.40 -11.515 (-12.13%) , RHHBY Roche $0.00 (0.00%) 05:21 04/10/19 04/10 05:21 04/10/19 05:21 Downgrade	Novartis, Roche rating change at Morgan Stanley » Novartis downgraded to… Novartis downgraded to Underweight from Equal Weight at Morgan Stanley. Morgan Stanley analyst Mark Purcell downgraded Novartis (NVS) to Underweight from Equal Weight and lowered his price target for the shares to 80 francs. The spinoff of Alcon will put more attention on the generics risk Novartis faces in its pharma business, Purcell tells investors in a research note. The analyst believes this generic pressure is not priced into shares of Novartis. His top pick remains Roche (RHHBY). NVS Novartis $83.40 -11.515 (-12.13%) RHHBY Roche $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Apr 17 Apr 24 Apr 18 Aug 19 Aug 02 Sep 04 Nov
CVS CVS Health $54.13 0.73 (1.37%) , ESRX Express Scripts $0.00 (0.00%) … 13:25 04/05/19 04/05 13:25 04/05/19 13:25 Periodicals	CMS head says insurers, PBMs can assume Medicare rebates in 2020, Axios reports » Seema Verma,… Seema Verma, Administrator of the Centers for Medicare & Medicaid Services, or CMS, said in a memo that insurers and pharmacy benefit managers can assume drug-pricing rebates in Medicare Part D will still exist as they design their 2020 plans, reported Axios' Bob Herman. The Trump administration has proposed eliminating such Medicare rebates beginning in 2020, the report noted. Pharmacy benefit managers include Express Scripts (ESRX), CVS Health (CVS) and UnitedHealth (UNH). Drug distributors include AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK). Publicly traded drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Reference Link CVS CVS Health $54.13 0.73 (1.37%) ESRX Express Scripts $0.00 (0.00%) UNH UnitedHealth $247.39 0.01 (0.00%) ABC AmerisourceBergen $78.07 2.095 (2.76%) CAH Cardinal Health $47.87 1 (2.13%) MCK McKesson $117.74 2.74 (2.38%) SNY Sanofi $44.01 -0.12 (-0.27%) PFE Pfizer $43.10 0.36 (0.84%) RHHBY Roche $0.00 (0.00%) GSK GlaxoSmithKline $41.63 -0.06 (-0.14%) AZN AstraZeneca $40.68 0.14 (0.35%) LLY Eli Lilly $126.49 0.855 (0.68%) JNJ Johnson & Johnson $135.93 0.34 (0.25%) BMY Bristol-Myers $46.88 0.185 (0.40%) MRK Merck $81.50 -0.31 (-0.38%) NVS Novartis $93.91 -0.34 (-0.36%) HUM Humana $273.57 2.35 (0.87%) CI Cigna $165.90 4.45 (2.76%) MOH Molina Healthcare $147.22 1.78 (1.22%) WCG WellCare $280.97 2.8 (1.01%) ANTM Anthem $291.19 0.05 (0.02%) HNT Health Net $0.00 (0.00%) CNC Centene $55.05 1.52 (2.84%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Apr 10 Apr 11 Apr 12 Apr 16 Apr 16 Apr 17 Apr 17 Apr 18 Apr 23 Apr 23 Apr 24 Apr 25 Apr 25 Apr 25 Apr 28 Apr 30 Apr 30 Apr 30 Apr 30 Apr 01 May 02 May 02 May 07 May 09 May 16 May 18 May 20 May 22 May 23 May 03 Jun 17 Jun 20 Jun 23 Jun 26 Jun 16 Jul 18 Aug 19 Aug 20 Sep 04 Nov
RHHBY Roche $0.00 (0.00%) 04:55 04/04/19 04/04 04:55 04/04/19 04:55 Conference/Events	Roche management to meet with Oppenheimer » Meeting to be held in San… Meeting to be held in San Francisco on April 4 hosted by Oppenheimer. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	04 Apr 17 Apr 18 Aug 19 Aug 04 Nov
AZN AstraZeneca $40.95 -0.95 (-2.27%) , NVS Novartis $94.63 -0.27 (-0.28%) … 10:47 04/03/19 04/03 10:47 04/03/19 10:47 Periodicals	Key House lawmakers reach deal to advanced drug pricing bill, The Hill says » House Energy and Commerce… House Energy and Commerce Committee Chairman Frank Pallone Jr. and Rep. Greg Walden, the panel's top Republican, have come to a bipartisan agreement to move forward long-stalled legislation aimed at lowering drug prices, The Hill's Peter Sullivan reports. The agreement is aimed at increasing competition from cheaper generic drugs and is expected to advanced from the committee on a bipartisan vote later on Wednesday, the publication adds. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).Reference Link AZN AstraZeneca $40.95 -0.95 (-2.27%) NVS Novartis $94.63 -0.27 (-0.28%) JNJ Johnson & Johnson $137.80 0.15 (0.11%) MRK Merck $83.48 0.33 (0.40%) BMY Bristol-Myers $46.80 0.1 (0.21%) RHHBY Roche $0.00 (0.00%) GSK GlaxoSmithKline $41.75 -0.13 (-0.31%) SNY Sanofi $43.87 -0.28 (-0.63%) LLY Eli Lilly $128.34 -1.02 (-0.79%) PFE Pfizer $42.96 0.05 (0.12%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	04 Apr 08 Apr 10 Apr 11 Apr 12 Apr 16 Apr 17 Apr 17 Apr 25 Apr 25 Apr 25 Apr 28 Apr 30 Apr 30 Apr 30 Apr 07 May 16 May 18 May 20 May 03 Jun 17 Jun 20 Jun 26 Jun 16 Jul 18 Aug 19 Aug 20 Sep 04 Nov

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial